Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy

BMC Gastroenterology

Liangxi Pan²  Lei Xia¹  Li Yao³  Liangjun Zhu²  Sheng Li² 

[1] Department of Pathology, Jiangsu Tumor Hospital, Nanjing 210000, China;Oncology, Jiangsu Tumor Hospital, NO.42 bai zi ting, Nanjing 210000, China;Department of Hematology, First Hospital Affiliated to Suzhou University, Suzhou 215000, China

关键词: Adjuvant chemotherapy;    Real-time PCR;    TS;    ERCC1;    Colorectal cancer;   

Others  :  1121827
DOI  :  10.1186/1471-230X-14-154

 received in 2014-01-17, accepted in 2014-08-21,  发布年份 2014

【 摘 要 】

Background

Aim was to explore the association of ERCC1 and TS mRNA levels with the disease free survival (DFS) in Chinese colorectal cancer (CRC) patients receiving oxaliplatin and 5-FU based adjuvant chemotherapy.

Methods

Total 112 Chinese stage II-III CRC patients were respectively treated by four different chemotherapy regimens after curative operation. The TS and ERCC1 mRNA levels in primary tumor were measured by real-time RT-PCR. Kaplan–Meier curves and log-rank tests were used for DFS analysis. The Cox proportional hazards model was used for prognostic analysis.

Results

In univariate analysis, the hazard ratio (HR) for the mRNA expression levels of TS and ERCC1 (logTS: HR = 0.820, 95% CI = 0.600 - 1.117, P = 0.210; logERCC1: HR = 1.054, 95% CI = 0.852 - 1.304, P = 0.638) indicated no significant association of DFS with the TS and ERCC1 mRNA levels. In multivariate analyses, tumor stage (IIIc: reference, P = 0.083; IIb: HR = 0.240, 95% CI = 0.080 - 0.724, P = 0.011; IIc: HR < 0.0001, P = 0.977; IIIa: HR = 0.179, 95% CI = 0.012 - 2.593, P = 0.207) was confirmed to be the independent prognostic factor for DFS. Moreover, the Kaplan-Meier DFS curves showed that TS and ERCC1 mRNA levels were not significantly associated with the DFS (TS: P = 0.264; ERCC1: P = 0.484).

Conclusion

The mRNA expression of ERCC1 and TS were not applicable to predict the DFS of Chinese stage II-III CRC patients receiving 5-FU and oxaliplatin based adjuvant chemotherapy.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover J, Parkin DM, Wardle J, Duffy SW, Cuzick J: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375(9726):1624-1633.
• [2]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [3]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [4]de Sousa E, Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP: Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011, 9(5):476-485.
• [5]Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, Komatsu H, Shindou H, Fukuoka H, Yoshinaga M: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 2003, 9(10):3700-3704.
• [6]Rubbia-Brandt L, Audard V, Sartoretti P, Roth A, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004, 15(3):460-466.
• [7]Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3(5):330-338.
• [8]Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R: Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998, 42(4):336-340.
• [9]Raymond E, Chaney S, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998, 9(10):1053-1071.
• [10]Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T-S, Rivera F: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019.
• [11]Benavides M, Pericay C, Valladares-Ayerbes M, Gil-Calle S, Massutí B, Aparicio J, Dueñas R, González-Flores E, Carrato A, Marcuello E: Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish cooperative group for the treatment of digestive tumors. Clin Colorectal Cancer 2012, 11(3):200-206.
• [12]Reed E: Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 1998, 27(1–3):187-201.
• [13]Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin J-C, Ducreux M, Sarasin A, Praz F: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005, 11(17):6212-6217.
• [14]Johnston PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995, 55(7):1407-1412.
• [15]Peters G, Backus H, Freemantle S, Van Triest B, Codacci-Pisanelli G, Van der Wilt C, Smid K, Lunec J, Calvert A, Marsh S: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochimica et Biophysica Acta (BBA)-Mol Basis Dis 2002, 158(2):194-205.
• [16]Lecomte T, Ferraz J-M, Zinzindohoué F, Loriot M-A, Tregouet D-A, Landi B, Berger A, Cugnenc P-H, Jian R, Beaune P: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004, 10(17):5880-5888.
• [17]Kim K, Yang S, Yoon Y, Lim SB, Yu C, Kim J: Validation of the seventh edition of the American joint committee on cancer tumor‒node‒metastasis (AJCC TNM) staging in patients with stage II and stage III colorectal carcinoma: analysis of 2511 cases from a medical centre in Korea. Colorectal Dis 2011, 13(8):e220-e226.
• [18]von Ahlfen S, Missel A, Bendrat K, Schlumpberger M: Determinants of RNA quality from FFPE samples. PLoS One 2007, 2(12):e1261.
• [19]Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Tsai PI: Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000, 4(2):135-142.
• [20]Shirota Y, Stoehlmacher J, Brabender J, Xiong Y-P, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz H-J: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19(23):4298-4304.
• [21]Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res 1996, 6(10):986-994.
• [22]Gibson U, Heid CA, Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 1996, 6(10):995-1001.
• [23]Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008, 3(6):1101-1108.
• [24]Kwon H, Roh M, Oh S, Kim S, Kim M, Kim J, Kim H: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007, 18(3):504-509.
• [25]Kim S-H, Kwon H-C, Oh SY, Lee DM, Lee S, Lee J-H, Roh M-S, Kim D-C, Park K-J, Choi H-J: Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase π for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 2009, 32(1):38-43.
• [26]Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, Cheung VG: Common genetic variants account for differences in gene expression among ethnic groups. Nat Genet 2007, 39(2):226-231.
• [27]Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8(7):2286-2291.
• [28]Bellmunt J, Paz-Ares L, Cuello M, Cecere F, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz J: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007, 18(3):522-528.
• [29]Mohiuddin M, Hayne M, Regine WF, Hanna N, Hagihara PF, McGrath P, Marks GM: Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Curr Treat Options Oncol 2000, 48(4):1075-1080.
• [30]Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR: Pathologic stage is most prognostic of disease‒free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008, 113(1):57-64.